Thyroid Eye Disease clinical trials at UCSD
3 in progress, 1 open to eligible people
Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
open to eligible people ages 18-80
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
La Jolla, California and other locations
Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sorry, in progress, not accepting new patients
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
La Jolla, California and other locations
Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
La Jolla, California and other locations
Last updated: